Last reviewed · How we verify
Palmitoylethanolamide sold as Levagen +
Palmitoylethanolamide is an endogenous fatty acid amide that modulates pain and inflammation by activating peroxisome proliferator-activated receptor alpha (PPAR-α) and reducing neuroinflammation.
Palmitoylethanolamide is an endogenous fatty acid amide that modulates pain and inflammation by activating peroxisome proliferator-activated receptor alpha (PPAR-α) and reducing neuroinflammation. Used for Neuropathic pain, Chronic pain conditions.
At a glance
| Generic name | Palmitoylethanolamide sold as Levagen + |
|---|---|
| Also known as | Levagen+ |
| Sponsor | RDC Clinical Pty Ltd |
| Drug class | PPAR-α agonist; endogenous lipid mediator |
| Target | PPAR-α (peroxisome proliferator-activated receptor alpha) |
| Modality | Small molecule |
| Therapeutic area | Pain management; Neurology |
| Phase | Phase 3 |
Mechanism of action
PEA is an endocannabinoid-like compound that acts as a ligand for PPAR-α, leading to downregulation of mast cell degranulation and microglial activation. This reduces the release of pro-inflammatory mediators and neuropeptides involved in pain signaling, thereby providing analgesic and anti-inflammatory effects without direct cannabinoid receptor activation.
Approved indications
- Neuropathic pain
- Chronic pain conditions
Common side effects
- Gastrointestinal disturbances
- Headache
- Dizziness
Key clinical trials
- The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema (PHASE2, PHASE3)
- A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palmitoylethanolamide sold as Levagen + CI brief — competitive landscape report
- Palmitoylethanolamide sold as Levagen + updates RSS · CI watch RSS
- RDC Clinical Pty Ltd portfolio CI